Cargando…

Short-chain fatty acids in patients with schizophrenia and ultra-high risk population

BACKGROUND: Individuals who experience the prodromal phase of schizophrenia (SCZ), a common and complex psychiatric disorder, are referred to as ultra-high-risk (UHR) individuals. Short-chain fatty acid (SCFA) is imperative in the microbiota-gut-brain axis and brain function. Accumulating amount of...

Descripción completa

Detalles Bibliográficos
Autores principales: Peng, Huiqing, Ouyang, Lijun, Li, David, Li, Zongchang, Yuan, Liu, Fan, Lejia, Liao, Aijun, Li, Jinguang, Wei, Yisen, Yang, Zihao, Ma, Xiaoqian, Chen, Xiaogang, He, Ying
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9790925/
https://www.ncbi.nlm.nih.gov/pubmed/36578297
http://dx.doi.org/10.3389/fpsyt.2022.977538
_version_ 1784859285288648704
author Peng, Huiqing
Ouyang, Lijun
Li, David
Li, Zongchang
Yuan, Liu
Fan, Lejia
Liao, Aijun
Li, Jinguang
Wei, Yisen
Yang, Zihao
Ma, Xiaoqian
Chen, Xiaogang
He, Ying
author_facet Peng, Huiqing
Ouyang, Lijun
Li, David
Li, Zongchang
Yuan, Liu
Fan, Lejia
Liao, Aijun
Li, Jinguang
Wei, Yisen
Yang, Zihao
Ma, Xiaoqian
Chen, Xiaogang
He, Ying
author_sort Peng, Huiqing
collection PubMed
description BACKGROUND: Individuals who experience the prodromal phase of schizophrenia (SCZ), a common and complex psychiatric disorder, are referred to as ultra-high-risk (UHR) individuals. Short-chain fatty acid (SCFA) is imperative in the microbiota-gut-brain axis and brain function. Accumulating amount of evidence shows the connections between psychiatric disorders and SCFAs. This study aims to explore the underlying roles SCFAs play in SCZ by investigating the association of alterations in SCFAs concentrations with common cognitive functions in both the SCZ and UHR populations. METHODS: The study recruited 59 SCZ patients (including 15 participants converted from the UHR group), 51 UHR participants, and 40 healthy controls (HC) within a complete follow-up of 2 years. Results of cognitive functions, which were assessed by utilizing HVLT-R and TMT, and serum concentrations of SCFAs were obtained for all participants and for UHR individuals at the time of their conversion to SCZ. RESULTS: Fifteen UHR participants converted to SCZ within a 2-year follow-up. Valeric acid concentration levels were lower in both the baseline of UHR individuals whom later converted to SCZ (p = 0.046) and SCZ patients (p = 0.036) than the HC group. Additionally, there were lower concentrations of caproic acid in the baseline of UHR individuals whom later transitioned to SCZ (p = 0.019) and the UHR group (p = 0.016) than the HC group. Furthermore, the caproic acid levels in the UHR group are significantly positively correlated with immediate memory (r = 0.355, p = 0.011) and negatively correlated with TMT-B (r = -0.366, p = 0.009). Significant differences in levels of acetic acid, butyric acid and isovaleric acid were absent among the three groups and in UHR individuals before and after transition to SCZ. CONCLUSION: Our study suggests that alterations in concentrations of SCFAs may be associated with the pathogenesis and the cognitive impairment of schizophrenia. Further researches are warranted to explore this association. The clinical implications of our findings were discussed.
format Online
Article
Text
id pubmed-9790925
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-97909252022-12-27 Short-chain fatty acids in patients with schizophrenia and ultra-high risk population Peng, Huiqing Ouyang, Lijun Li, David Li, Zongchang Yuan, Liu Fan, Lejia Liao, Aijun Li, Jinguang Wei, Yisen Yang, Zihao Ma, Xiaoqian Chen, Xiaogang He, Ying Front Psychiatry Psychiatry BACKGROUND: Individuals who experience the prodromal phase of schizophrenia (SCZ), a common and complex psychiatric disorder, are referred to as ultra-high-risk (UHR) individuals. Short-chain fatty acid (SCFA) is imperative in the microbiota-gut-brain axis and brain function. Accumulating amount of evidence shows the connections between psychiatric disorders and SCFAs. This study aims to explore the underlying roles SCFAs play in SCZ by investigating the association of alterations in SCFAs concentrations with common cognitive functions in both the SCZ and UHR populations. METHODS: The study recruited 59 SCZ patients (including 15 participants converted from the UHR group), 51 UHR participants, and 40 healthy controls (HC) within a complete follow-up of 2 years. Results of cognitive functions, which were assessed by utilizing HVLT-R and TMT, and serum concentrations of SCFAs were obtained for all participants and for UHR individuals at the time of their conversion to SCZ. RESULTS: Fifteen UHR participants converted to SCZ within a 2-year follow-up. Valeric acid concentration levels were lower in both the baseline of UHR individuals whom later converted to SCZ (p = 0.046) and SCZ patients (p = 0.036) than the HC group. Additionally, there were lower concentrations of caproic acid in the baseline of UHR individuals whom later transitioned to SCZ (p = 0.019) and the UHR group (p = 0.016) than the HC group. Furthermore, the caproic acid levels in the UHR group are significantly positively correlated with immediate memory (r = 0.355, p = 0.011) and negatively correlated with TMT-B (r = -0.366, p = 0.009). Significant differences in levels of acetic acid, butyric acid and isovaleric acid were absent among the three groups and in UHR individuals before and after transition to SCZ. CONCLUSION: Our study suggests that alterations in concentrations of SCFAs may be associated with the pathogenesis and the cognitive impairment of schizophrenia. Further researches are warranted to explore this association. The clinical implications of our findings were discussed. Frontiers Media S.A. 2022-12-12 /pmc/articles/PMC9790925/ /pubmed/36578297 http://dx.doi.org/10.3389/fpsyt.2022.977538 Text en Copyright © 2022 Peng, Ouyang, Li, Li, Yuan, Fan, Liao, Li, Wei, Yang, Ma, Chen and He. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Psychiatry
Peng, Huiqing
Ouyang, Lijun
Li, David
Li, Zongchang
Yuan, Liu
Fan, Lejia
Liao, Aijun
Li, Jinguang
Wei, Yisen
Yang, Zihao
Ma, Xiaoqian
Chen, Xiaogang
He, Ying
Short-chain fatty acids in patients with schizophrenia and ultra-high risk population
title Short-chain fatty acids in patients with schizophrenia and ultra-high risk population
title_full Short-chain fatty acids in patients with schizophrenia and ultra-high risk population
title_fullStr Short-chain fatty acids in patients with schizophrenia and ultra-high risk population
title_full_unstemmed Short-chain fatty acids in patients with schizophrenia and ultra-high risk population
title_short Short-chain fatty acids in patients with schizophrenia and ultra-high risk population
title_sort short-chain fatty acids in patients with schizophrenia and ultra-high risk population
topic Psychiatry
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9790925/
https://www.ncbi.nlm.nih.gov/pubmed/36578297
http://dx.doi.org/10.3389/fpsyt.2022.977538
work_keys_str_mv AT penghuiqing shortchainfattyacidsinpatientswithschizophreniaandultrahighriskpopulation
AT ouyanglijun shortchainfattyacidsinpatientswithschizophreniaandultrahighriskpopulation
AT lidavid shortchainfattyacidsinpatientswithschizophreniaandultrahighriskpopulation
AT lizongchang shortchainfattyacidsinpatientswithschizophreniaandultrahighriskpopulation
AT yuanliu shortchainfattyacidsinpatientswithschizophreniaandultrahighriskpopulation
AT fanlejia shortchainfattyacidsinpatientswithschizophreniaandultrahighriskpopulation
AT liaoaijun shortchainfattyacidsinpatientswithschizophreniaandultrahighriskpopulation
AT lijinguang shortchainfattyacidsinpatientswithschizophreniaandultrahighriskpopulation
AT weiyisen shortchainfattyacidsinpatientswithschizophreniaandultrahighriskpopulation
AT yangzihao shortchainfattyacidsinpatientswithschizophreniaandultrahighriskpopulation
AT maxiaoqian shortchainfattyacidsinpatientswithschizophreniaandultrahighriskpopulation
AT chenxiaogang shortchainfattyacidsinpatientswithschizophreniaandultrahighriskpopulation
AT heying shortchainfattyacidsinpatientswithschizophreniaandultrahighriskpopulation